The expression of
phosphoglycerate kinase 1 (MMP19) is elevated in some
cancers. However, the clinical features and prognostic value of
glioma patients with MMP19 expression are unclear. In this study, the expression level of MMP19 and the correlation between the level of MMP19 expression and the clinicopathologic data in
glioma patients including survival were examined.
METHODS AND RESULTS: Using real-time PCR, the
mRNA expression of MMP19 was examined in 61 fresh
glioma tissues and 32 brain samples. The result indicated that MMP19
mRNA was obviously elevated in
glioma tissues compared to brain tissues. Further, we observed that MMP19
mRNA was much higher in stage III patients than it was in stage I-II patients. The expression of the MMP19
protein was determined by immunohistochemical analysis in 156
paraffin-embedded
glioma samples and 35 normal
paraffin-embedded brain samples. The MMP19
protein level was significantly increased in
glioma tissues compared to brain tissues (P = 0.008). Furthermore, we observed that a high expression of MMP19
protein was positively associated with clinical stage (P = 0.008) but did not correlate with age, gender, or histological type. An increased MMP19
protein expression was associated with poor overall survival rates (P = 0.001). A stratified analysis showed that patients with high MMP19
protein expression indicated a worse prognosis occurring in WHO III-IV stages (P = 0.001). A Multivariate analysis indicated that a high expression of the MMP19
protein was an independent prognostic
indicator of patient survival (P = 0.009).
CONCLUSIONS: